Hengrui Pharma
GSK Strengthens COPD Offering via $12 Billion Multi-Program Deal with China’s Hengrui Pharma
GSK; Hengrui Pharma; COPD; biobucks; PDE3/4 inhibitor; HRS-9821; Nucala; immunology; oncology; licensing deal
Actionable Insights Powered by AI
GSK; Hengrui Pharma; COPD; biobucks; PDE3/4 inhibitor; HRS-9821; Nucala; immunology; oncology; licensing deal